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ScienceDirectIn the last decade, progress in the analysis of the human
immune response and in the isolation of human monoclonal
antibodies have provided an innovative approach to the
identification of protective antigens which are the basis for the
design of vaccines capable of eliciting effective B-cell
immunity. In this review we illustrate, with relevant examples,
the power of this approach that can rapidly lead to the
identification of protective antigens in complex pathogens,
such as human cytomegalovirus and Plasmodium falciparum,
and of conserved sites in highly variable antigens, such as
influenza hemagglutinin and HIV-1 Env. We will also discuss
how the genealogical analysis of antigen-stimulated B cell
clones provides the basis to delineate the best suitable prime-
boost vaccination strategy for the induction of broadly
neutralizing antibodies.
Addresses
1 Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500
Bellinzona, Switzerland
2 Institute of Microbiology, ETH Zu¨rich, Vladimir-Prelog-Weg 1, 8093
Zu¨rich, Switzerland
3 Humabs BioMed, Via Mirasole 1, 6500 Bellinzona, Switzerland
Corresponding author: Lanzavecchia, Antonio (lanzavecchia@irb.usi.ch)
Current Opinion in Immunology 2016, 41:62–67
This review comes from a themed issue on Vaccines
Edited by Rino Rappuoli and Ennio De Gregorio
For a complete overview see the Issue and the Editorial
Available online 22nd June 2016
http://dx.doi.org/10.1016/j.coi.2016.06.001
0952-7915/# 2016 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
Introduction
When our immune system is challenged by an infectious
agent, a polyclonal antibody response is generated against
multiple protein and non-protein antigens. The extent of
the response reflects the immunogenicity of the individ-
ual components, which is determined by multiple factors
such as their abundance, their complexity and their
capacity to bind to cellular receptor and trigger innate
immunity, not to mention the influence of pre-existing
immunity. In general, only a fraction of the antibodies
produced exerts protective activity by binding toCurrent Opinion in Immunology 2016, 41:62–67 molecules that are required for invasion or virulence or
by eliciting effector mechanisms. For instance, the largest
fraction of antibodies produced in response to a virus
infection is directed against internal or surface proteins in
a denatured or post-fusion conformation and is therefore
devoid of neutralizing activity [1,2,3]. Thus, the immu-
nogenicity of the most abundant proteins offers to the
pathogen the opportunity to limit the most effective
response by a mechanism of antigenic competition.
In this review we discuss how recent advances in the
characterization of the neutralizing antibody response to
human pathogens, combined with advanced protein en-
gineering methods, have provided a new way to solve the
problem of antigenic competition and have led to the
production of vaccine candidates that elicit antibody
responses of high magnitude and specific activity.
Analytic vaccinology: the cases of HCMV and
malaria
Human cytomegalovirus (HCMV) is a herpes virus that
establishes a lifelong infection in healthy individuals, but
causes serious pathology in the fetus and in immunosup-
pressed patients and has been associated with immune
senescence and atherosclerosis [4]. HCMV uses multiple
glycoprotein complexes for binding and fusion to host cells
and has a broad cell tropism, being able to infect fibroblasts
as well as epithelial, endothelial and myeloid cells [5]. The
fusion protein gB has been considered the most obvious
vaccine candidate but clinical trials with recombinant gB
(in the post-fusion conformation) has shown limited effi-
cacy [6]. To identify the most potent HCMV vaccine, an
analytic vaccinology approach was used to isolate, from
memory B cells of naturally infected donors, a large panel
of monoclonal antibodies selected for their capacity to
neutralize HCMV infection of multiple cell types [7]
(Figure 1). This approach led to the identification of a
new class of antibodies that were 1000 fold more potent
that antibodies to gB in neutralizing HCMV infection of
epithelial, endothelial and myeloid cells. These antibodies
were mapped to nine distinct sites on the gH/gL/UL128-
131A complex, a pentameric complex that was previously
found to be required for infection of those cell types [8].
The identification of the pentamer as the target of the most
potent antibodies was subsequently confirmed by several
studies [9,10,11]. As an example, a soluble pentamer
produced by stably a transfected CHO cell line elicited in
mice antibody titers that persisted to high levels over timewww.sciencedirect.com
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Antibody-guided vaccine design. Human monoclonal antibodies isolated from immune donors are used to identify protective antigens and
epitopes. The antigens discovered from complex pathogens are produced as recombinant proteins (path 1; e.g. HCMV pentamer) and, when
necessary, engineered for increased stability (path 2; e.g. stabilized pre-fusion HRSV F protein) or modified to express particular domains or
epitopes (path 3; e.g. head-less HA or Palivizumab epitope displayed on VLPs).and that were 300-1000 fold higher than those found in
individuals that recovered from primary HCMV infection
[10]. Importantly, the antibodies elicited by the penta-
mer vaccine prevented cell-to-cell spread and viral dis-
semination from endothelial cells to leukocytes and
neutralized infection of both epithelial cells and fibroblasts
due to the production of antibodies to the gH glycoprotein,
which is required for fibroblasts infection.www.sciencedirect.com The target-agnostic approach can be particularly useful to
identify targets in complex pathogens such as bacteria
and parasites. An interesting example regards the identi-
fication of variant surface antigens (VSAs) which are
present on the surface of Plasmodium falciparum (Pf)-
infected erythrocytes and mediate adhesion to endothe-
lia, leading to pathology. The VSAs are encoded by more
that 200 genes that are polymorphic and clonallyCurrent Opinion in Immunology 2016, 41:62–67
64 Vaccinesexpressed, thus providing the pathogen with a powerful
mechanism of escape from the antibody response. Human
monoclonal antibodies isolated from multiparous women
have been used to identify VAR2CSA as the primary
target of antibodies that protect from placental malaria
[12]. In a more recent study, Tan et al. isolated several
antibodies that broadly react with erythrocytes infected
with different Pf isolates and identified the target anti-
gens as distinct RIFINs [13]. Surprisingly, these anti-
bodies acquired their broad reactivity through a novel
mechanism of insertion of a large DNA fragment between
the V and DJ segments. The insert originates from
chromosome 19 and encodes the extracellular domain
of the collagen-binding inhibitory receptor LAIR-1,
which is both necessary and sufficient for binding to
RIFINs. Importantly, the LAIR-1 domain carries somatic
mutations that abolish binding to collagen and increase
binding to infected erythrocytes. These findings illus-
trate, with a biologically relevant example, a novel mech-
anism of antibody diversification and demonstrate the
existence of conserved epitopes as candidates for the
development of a malaria vaccine [14].
Structure-based vaccinology: the case of
HRSV
Human respiratory syncytial virus (HRSV) is the most
prominent viral agent of pediatric respiratory infections.
Currently, the only treatment available is Palivizumab
[15], a humanized monoclonal antibody that binds to an
epitope that is conserved in the pre-fusion and post-
fusion conformation of the HRSV F protein [16]. On
the basis of the properties of Palivizumab, the initial
efforts towards an HRSV vaccine were focused on the
use of the post-fusion F-protein that was engineered
to increase its solubility, resulting into highly stable
immunogen forms, that were tested either as soluble
antigens or displayed onto virus-like particles (VLPs)
[17,18].
Two recent studies used the structural information on the
Palivizumab linear epitope, a 24 amino acid helix–loop–
helix structure, to develop epitope-focused vaccines.
Correia et al. used computational protein design to gen-
erate stable protein scaffolds that accurately mimic the
Palivizumab epitope and, when chemically linked to
VLPs, induce HRSV-neutralizing antibodies in macaques
[19]. In a subsequent study, Milich and coworkers used
an empirical approach by directly inserting the Palivizu-
mab epitope in VLPs composed of woodchuck hepadna-
virus core (WHcAg) protein, which were then selected
with the antibody and found to be immunogenic in
rodents [20]. While these studies provide for the first
time a proof-of-principle for epitope-focused vaccinology
(Figure 1), it is not evident what could be the advantage
of limiting the response to a single epitope, given the
presence of several conserved epitopes in the HRSV F
protein.Current Opinion in Immunology 2016, 41:62–67 The analysis of the human antibody response to HRSV
[21,22] and the isolation of human neutralizing monoclo-
nal antibodies [23,24] showed that the large majority of
HRSV neutralizing antibodies elicited by natural infection
are specific for the pre-fusion F protein conformation and,
unlike Palivizumab, do not cross-react with the post-fusion
conformation. On the basis of these observations and on
the crystal structure of the pre-fusion F protein in complex
with a neutralizing antibody [25], Kwong and coworkers
used structure-based design to produce a stabilized HRSV
F protein through the introduction of cysteine residues
and the filling of hydrophobic cavities [26,27]. This
protein (dubbed DS-Cav1) maintained binding to potent
neutralizing antibodies and was able to elicit in mice and
macaques levels of HRSV-neutralizing antibodies that
exceeded the protective threshold. These results provide
a clear example of structure-driven vaccinology to gener-
ate stable immunogens capable of inducing a polyclonal
response to multiple neutralizing epitopes of viral fusion
proteins, overcoming the problem of their intrinsic insta-
bility (Figure 1).
Epitope-focused vaccinology: the cases of
influenza A
Influenza A and HIV-1 are the prototypes of viruses that
evade the antibody response by continuously mutating
surface glycoproteins. However, certain sites are relative-
ly conserved since they are required for infectivity and
fusion and can be therefore exploited to design vaccines
capable of inducing broad protection. In the last decade
the isolation of broadly neutralizing antibodies has pro-
vided a powerful platform to identify such epitopes, thus
speeding up vaccine design efforts [28,29].
The sialic acid binding pocket of influenza hemagglutinin
(HA) is a conserved site that can be targeted by anti-
bodies, such as CH65, that carry at the tip of HCDR3 a
distinct motif that mimics sialic acid [30]. Importantly,
these antibodies arise from diverse germline origins and
affinity maturation pathways, suggesting that such an
antibody response could be rapidly generated by appro-
priate immunogens. However, the breadth of these anti-
bodies is somewhat limited due to the presence of highly
variable residues that flank the receptor binding site.
The HA stem is a more conserved region which has been
shown to be recognized by different families of broadly
neutralizing antibodies that recognize multiple subtypes
in group 1 [31–34], group 2 [35] and, in some cases, both
group 1 and group 2 influenza A viruses [36,37,38].
Recently, Pappas et al. showed that most individuals
make antibodies that broadly recognize group 1 subtypes.
This public antibody response relies exclusively on the H
chain, which is encoded by VH1-69 alleles with phenyl-
alanine at position 54 and a short HCDR3 with tyrosine at
position 98. Interestingly, through the reconstruction of
the developmental pathways of several such clones, it waswww.sciencedirect.com
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cases by a single mutation [39]. These findings explain
the high frequency of antibodies specific for the stem of
group 1 HAs. In contrast, antibodies that recognize both
group 1 and group 2 HAs are much less frequent since
they use different VH/VL genes. Furthermore they are
generated through a complex developmental pathway,
being first selected for their germ-line reactivity against
group 1 and subsequently acquiring group 2 reactivity
through somatic mutations [36]. The latter finding sug-
gests that the rare pan-influenza A neutralizing antibodies
might be elicited using an appropriate heterologous
prime-boost strategy.
The identification of the HA stem as a conserved site of
influenza HA has raised the possibility of developing a
universal influenza vaccine [40]. Two approaches have
been developed towards this ambitious goal. The first
involves a prime-boost strategy using chimeric HA mole-
cules carrying the same stem combined with heterolo-
gous heads [41,42] and is based on the classical principle
of the original antigenic sin that represents in this case a
natural mechanism of immunofocusing. The second
approach of epitope-focused vaccinology involves the
production of headless HAs [43] (Figure 1). In a recent
report, Yassine et al. used iterative cycles of structure-
based design to produce a stabilized  stem immunogen,
HA-SS, genetically fused to ferritin nanoparticles, which
is recognized by stem-specific monoclonal antibodies
and elicits, in mice and ferrets, broadly cross-reactive
antibodies [44]. In general, the assemblies of multiple
copies of subunit antigens in well-ordered arrays, such as
in the case of ferritin or VLPs, offer the advantage of
mimicking the repetitiveness of most natural pathogens
surface proteins potentially providing improved antigen
stability and immunogenicity [45,46]. In an another
study, Impagliazzo et al. used a rational design combined
with a library approach to generate a HA stem antigen
called mini-HA that protects mice and non-human pri-
mates from lethality and symptoms [47]. It should be
noted that in both studies the neutralizing antibody
levels induce by the vaccine were modest, suggesting
that in vivo protection may be achieved through a com-
bination of neutralization and Fc-dependent effector
function, which is known to be elicited by anti-stem
antibodies [36,48,49]. The headless HA vaccine has
been shown to work for group 1 influenza viruses and
should be extended to group 2 viruses, and possibly to
influenza B, in order to fully realize the dream of a
universal influenza vaccine.
Factors that limit the antibody response: the
challenge of HIV-1
An effective antibody response is limited by the frequen-
cy of antigen-specific B cells in the naı¨ve repertoire, by
the number of mutations required to reach high affinity or
breadth, and by the availability of T cell help. Thus, anwww.sciencedirect.com ideal vaccine should contain a sufficiently high number of
T and B cell epitopes and should be formulated to
effectively prime the germinal center reaction [50]. In
addition, the finding that preexisting immunity can shape
the antibody response to new structurally related antigens
[51–53] suggests modalities of prime-boost immunization
to optimize the antibody response [54].
Recent technological advances are increasingly used to
investigate the developmental pathways leading to po-
tent and broadly neutralizing antibodies. These include
the in depth analysis of the antibody response through the
isolation of multiple cells within the same lineage, possi-
bly implemented by next generation sequencing and
deconvolution of the serum antibody repertoire through
LC–MS/MS analysis [39,55,56]. The systematic recon-
struction of the genealogy trees of antibody lineages has
shown that neutralizing antibodies to influenza or HRSV
mature rapidly [39] or may not even need affinity
maturation, while somatic mutations are critical to
achieve breadth [23,36]. The situation is strikingly dif-
ferent in the case of HIV-1, where viruses and B cells co-
evolve over a period of years, leading to a slow and
infrequent development of broadly neutralizing antibo-
dies [57]. In the last decade many new broadly neutraliz-
ing antibodies of high potency have been isolated and
new sites of vulnerability on the Env protein have been
defined. Importantly, in the last few years cryo-EM and
crystallography were used to finally solve the structure of
a stabilized soluble Env trimer molecule (i.e. BG505
SOSIP), alone or in combination with several broadly
neutralizing antibodies [58–60]. These constructs are now
considered a relevant mimic of the native functional
trimer being recognized preferentially by neutralizing
antibodies. The HIV-1 broadly neutralizing antibodies
are found only in a fraction of infected individual and
have a slow and complex developmental pathway or
derive from very rare precursors characterized by ex-
tremely long HCDR3. These observations have led to
the proposal of a prime-boost strategy with different
antigens that target the naı¨ve precursors and different
stages of the antibody developmental pathway defined as
‘B cell-lineage vaccine design’ [61].
These hurdles represent a significant challenge to the
development of an effective HIV-1 vaccine. However,
these efforts contributed to the development of novel
vaccine design strategies that represent a fertile ground
for significant advances in the generation of new and
better vaccines against other pathogens.
Acknowledgements
We thank Siro Bianchi for the help in the preparation of the figure.
The work in Lanzavecchia’s laboratory is supported by the European
Research Council (grant no. 250348 IMMUNExplore and 670955
BROADimmune), the Swiss National Science Foundation (grant no.
160279), the Swiss Vaccine Research Institute.Current Opinion in Immunology 2016, 41:62–67
66 VaccinesReferences and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Pinna D, Corti D, Jarrossay D, Sallusto F, Lanzavecchia A: Clonal
dissection of the human memory B-cell repertoire following
infection and vaccination. Eur J Immunol 2009, 39:1260-1270.
2. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F,
Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D,
Balla-Jhagjhoorsingh S et al.: Analysis of memory B cell
responses and isolation of novel monoclonal antibodies with
neutralizing breadth from HIV-1-infected individuals. PLoS
ONE 2010, 5:e8805.
3. Po¨tzsch S, Spindler N, Wiegers A-K, Fisch T, Ru¨cker P, Sticht H,
Grieb N, Baroti T, Weisel F, Stamminger T et al.: B cell repertoire
analysis identifies new antigenic domains on glycoprotein B of
human cytomegalovirus which are target of neutralizing
antibodies. PLoS Pathog 2011, 7:e1002172.
4. Kenneson A, Cannon MJ: Review and meta-analysis of the
epidemiology of congenital cytomegalovirus (CMV) infection.
Rev Med Virol 2007, 17:253-276.
5. Compton T: Receptors and immune sensors: the complex
entry path of human cytomegalovirus. Trends Cell Biol 2004,
14:5-8.
6. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L,
Corey L, Hill J, Davis E, Flanigan C et al.: Vaccine prevention of
maternal cytomegalovirus infection. N Engl J Med 2009,
360:1191-1199.
7. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A,
Revello MG, Gerna G, Sallusto F, Lanzavecchia A: Isolation of
human monoclonal antibodies that potently neutralize human
cytomegalovirus infection by targeting different epitopes on
the gH/gL/UL128-131A complex. J Virol 2010, 84:1005-1013.
8. Wang D, Shenk T: Human cytomegalovirus virion protein
complex required for epithelial and endothelial cell tropism.
Proc Natl Acad Sci U S A 2005, 102:18153-18158.
9. Loughney JW, Rustandi RR, Wang D, Troutman MC, Dick LW, Li G,
Liu Z, Li F, Freed DC, Price CE et al.: Soluble human
cytomegalovirus gH/gL/pUL128-131 pentameric complex, but
not gH/gL, inhibits viral entry to epithelial cells and presents




Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S,
Preite S, Fuschillo D, Percivalle E, Sallusto F et al.: Antibody-
driven design of a human cytomegalovirus gHgLpUL128L
subunit vaccine that selectively elicits potent neutralizing
antibodies. Proc Natl Acad Sci U S A 2014, 111:17965-17970.




Hofmann I, Wen Y, Ciferri C, Schulze A, Fu¨hner V, Leong M,
Gerber A, Gerrein R, Nandi A, Lilja AE et al.: Expression of the
human cytomegalovirus pentamer complex for vaccine use in
a CHO system. Biotechnol Bioeng 2015, 112:2505-2515.
With [10] provides evidence for the immunogenicity of a HCMV penta-
meric vaccine.
12. Barfod L, Bernasconi NL, Dahlba¨ck M, Jarrossay D, Andersen PH,
Salanti A, Ofori MF, Turner L, Resende M, Nielsen MA et al.:
Human pregnancy-associated malaria-specific B cells target




Tan J, Pieper K, Piccoli L, Abdi A, Foglierini M, Geiger R,
Maria Tully C, Tully CM, Jarrossay D, Ndungu FM et al.: A LAIR1
insertion generates broadly reactive antibodies against
malaria variant antigens. Nature 2015, 529:105-109.
Broadly reactive antibodies to malaria antigens generated by a new
mechanism of DNA transposition.
14. Robbiani DF, Nussenzweig RS: A new way to diversify
antibodies by DNA transposition. Cell 2016, 164:601-602.Current Opinion in Immunology 2016, 41:62–67 15. Palivizumab, a humanized respiratory syncytial virus
monoclonal antibody, reduces hospitalization from
respiratory syncytial virus infection in high-risk infants.
Pediatrics 1998, 102:531-537.
16. McLellan JS, Yang Y, Graham BS, Kwong PD: Structure of
respiratory syncytial virus fusion glycoprotein in the
postfusion conformation reveals preservation of neutralizing
epitopes. J Virol 2011, 85:7788-7796.
17. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R,
Mandl CW, Dormitzer PR, Carfi A: Structural basis for
immunization with postfusion respiratory syncytial virus
fusion F glycoprotein (RSV F) to elicit high neutralizing
antibody titers. Proc Natl Acad Sci U S A 2011, 108:9619-9624.
18. Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M,
Zhou B, Lu H, Boddapati S, Li J et al.: Respiratory syncytial virus
fusion glycoprotein expressed in insect cells form protein
nanoparticles that induce protective immunity in cotton rats.
PLoS ONE 2012, 7:e50852.
19.

Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG,
Rupert P, Correnti C, Kalyuzhniy O, Vittal V et al.: Proof of
principle for epitope-focused vaccine design. Nature 2014,
507:201-206.
Together with [20] provides an example of epitope-focused vaccinology.
20.

Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ,
Jones JE, Peterson DL, McCarthy MP, Van Nest G et al.:
Palivizumab epitope-displaying virus-like particles protect
rodents from RSV challenge. J Clin Invest 2015, 125:1637-1647.
Together with [19] provides an example of epitope-focused vaccinology.
21. Magro M, Mas V, Chappell K, Va´zquez M, Cano O, Luque D,
Terro´n MC, Melero JA, Palomo C: Neutralizing antibodies
against the preactive form of respiratory syncytial virus fusion
protein offer unique possibilities for clinical intervention. Proc
Natl Acad Sci U S A 2012, 109:3089-3094.
22. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M,
Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang G-Y et al.:
Prefusion F-specific antibodies determine the magnitude of
RSV neutralizing activity in human sera. Sci Transl Med 2015, 7
309ra162–309ra162.
23. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G,
Guarino B, Silacci C, Marcandalli J, Marsland BJ et al.: Cross-
neutralization of four paramyxoviruses by a human
monoclonal antibody. Nature 2013, 501:439-443.
24. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ,
van Geelen CMM, Lukens MV, van Bleek GM, Widjojoatmodjo MN,
Bogers WMJM, Mei H et al.: Generation of stable monoclonal
antibody-producing B cell receptor–positive human memory B
cells by genetic programming. Nat Med 2009, 16:123-128.
25. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T,
Baxa U, Yasuda E, Beaumont T et al.: Structure of RSV fusion
glycoprotein trimer bound to a prefusion-specific neutralizing
antibody. Science 2013, 340:1113-1117.
26.

McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE,
Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A et al.: Structure-
based design of a fusion glycoprotein vaccine for respiratory
syncytial virus. Science 2013, 342:592-598.
A remarkable example of structure-based design of a stabilized pre-
fusion RSV F protein vaccine.
27. Stewart-Jones GBE, Thomas PV, Chen M, Druz A, Joyce MG,
Kong W-P, Sastry M, Soto C, Yang Y, Zhang B et al.: A cysteine
zipper stabilizes a pre-fusion F glycoprotein vaccine for
respiratory syncytial virus. PLOS ONE 2015, 10:e0128779.
28. Corti D, Lanzavecchia A: Broadly neutralizing antiviral
antibodies. Annu Rev Immunol 2013, 31:705-742.
29. Burton DR, Hangartner L: Broadly neutralizing antibodies to HIV




Schmidt AG, Therkelsen MD, Stewart S, Kepler TB, Liao H-X,
Moody MA, Haynes BF, Harrison SC: Viral receptor-binding site
antibodies with diverse germline origins. Cell 2015, 161:1-18.
Describes a common motif used by antibodies that bind to the receptor
binding site of influenza HA.www.sciencedirect.com
Antibody-guided vaccine design Lanzavecchia et al. 6731. Throsby M, van den Brink E, Jongeneelen M, Poon LLM, Alard P,
Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y et al.:
Heterosubtypic neutralizing monoclonal antibodies cross-
protective against H5N1 and H1N1 recovered from human
IgM+ memory B cells. PLoS ONE 2008, 3:e3942-e4015.
32. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen L-M, Santelli E,
Stec B, Cadwell G, Ali M et al.: Structural and functional bases
for broad-spectrum neutralization of avian and human
influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
33. Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-
Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ,
Temperton NJ et al.: Heterosubtypic neutralizing antibodies are
produced by individuals immunized with a seasonal influenza
vaccine. J Clin Invest 2010, 120:1663-1673.
34. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J,
Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI
et al.: Broadly cross-reactive antibodies dominate the human
B cell response against 2009 pandemic H1N1 influenza virus
infection. J Exp Med 2011, 208:181-193.
35. Ekiert DC, Friesen RHE, Bhabha G, Kwaks T, Jongeneelen M,
Yu W, Ophorst C, Cox F, Korse HJWM, Brandenburg B et al.: A
highly conserved neutralizing epitope on group 2 influenza A
viruses. Science 2011, 333:843-850.
36.

Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D,
Vachieri SG, Pinna D, Minola A, Vanzetta F et al.: A neutralizing
antibody selected from plasma cells that binds to group 1 and
group 2 influenza A hemagglutinins. Science 2011, 333:850-
856.
First example of a pan-influenza A neutralizing antibody.
37. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R,
Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M et al.:
Highly conserved protective epitopes on influenza B viruses.
Science 2012, 337:1343-1348.
38. Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, Fong R,
Yan D, Kim J, Zhang J et al.: An in vivo human-plasmablast
enrichment technique allows rapid identification of




Pappas L, Foglierini M, Piccoli L, Kallewaard NL, Turrini F,
Silacci C, Fernandez-Rodriguez B, Agatic G, Giacchetto-Sasselli I,
Pellicciotta G et al.: Rapid development of broadly influenza
neutralizing antibodies through redundant mutations. Nature
2014, 516:418-422.
Describes the requirements and developmental pathway of broadly
influenza neutralizing antibodies.
40. Yewdell JW: To dream the impossible dream: universal
influenza vaccination. Curr Opin Virol 2013, 3:316-321.
41. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J,
Margine I, Albrecht RA, Palese P: Influenza viruses expressing
chimeric hemagglutinins: globular head and stalk domains
derived from different subtypes. J Virol 2012, 86:5774-5781.
42. Krammer F, Palese P: Universal influenza virus vaccines: need
for clinical trials. Nat Immunol 2014, 15:3-5.
43. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcı´a-
Sastre A, Palese P: Influenza virus vaccine based on the
conserved hemagglutinin stalk domain. mBio 2010, 1 e00018-10.
44.

Yassine HM, Boyington JC, McTamney PM, Wei C-J, Kanekiyo M,
Kong W-P, Gallagher JR, Wang L, Zhang Y, Joyce MG et al.:
Hemagglutinin-stem nanoparticles generate heterosubtypic
influenza protection. Nat Med 2015, 21:1065-1070.
With [47] shows an example of epitope-focused vaccine based on
influenza HA stem.
45. Lo´pez-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ: Self-
assembling protein nanoparticles in the design of vaccines.
Comput Struct Biotechnol J 2016, 14:58-68.www.sciencedirect.com 46. King NP, Bale JB, Sheffler W, McNamara DE, Gonen S, Gonen T,
Yeates TO, Baker D: Accurate design of co-assembling multi-
component protein nanomaterials. Nature 2014, 510:103-108.
47.

Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X,
Hoffman RMB, van Meersbergen R, Huizingh J, Wanningen P,
Verspuij J et al.: A stable trimeric influenza hemagglutinin
stem as a broadly protective immunogen. Science 2015,
349:1301-1306.
With [44] shows an example of epitope-focused vaccine based on
influenza HA stem.
48. DiLillo DJ, Tan GS, Palese P, Ravetch JV: Broadly neutralizing
hemagglutinin stalk-specific antibodies require FcgR
interactions for protection against influenza virus in vivo. Nat
Med 2014, 20:143-151.
49. DiLillo DJ, Palese P, Wilson PC, Ravetch JV: Broadly neutralizing
anti-influenza antibodies require Fc receptor engagement for
in vivo protection. J Clin Invest 2016, 126:605-610.
50. Victora GD, Nussenzweig RS: Germinal centers. Annu Rev
Immunol 2012, 30:429-457.
51. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT,
Henry Dunand CJ, Taylor WM, Lim S, Huang M et al.: Immune
history profoundly affects broadly protective B cell responses
to influenza. Sci Transl Med 2015, 7 316ra192–316ra192.
52. Andrews SF, Kaur K, Pauli NT, Huang M, Huang Y, Wilson PC:
High preexisting serological antibody levels correlate with
diversification of the influenza vaccine response. J Virol 2015,
89:3308-3317.
53. Huang K-YA, Rijal P, Schimanski L, Powell TJ, Lin T-Y,
McCauley JW, Daniels RS, Townsend AR: Focused antibody
response to influenza linked to antigenic drift. J Clin Invest
2015, 125:2631-2645.
54. Wang S, Mata-Fink J, Kriegsman B, Hanson M, Irvine DJ,
Eisen HN, Burton DR, Wittrup KD, Kardar M, Chakraborty AK:
Manipulating the selection forces during affinity maturation to
generate cross-reactive HIV antibodies. Cell 2015, 160:
785-797.
55. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X,
Longo NS, Louder M, McKee K et al.: Focused evolution of HIV-1
neutralizing antibodies revealed by structures and deep
sequencing. Science 2011, 333:1593-1602.
56. Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR,
Georgiou G: The promise and challenge of high-throughput
sequencing of the antibody repertoire. Nat Biotechnol 2014,
32:158-168.
57. Liao H-X, Lynch R, Zhou T, Gao F, MunirAlam S, Boyd SD, Fire AZ,
Roskin KM, Schramm CA, Zhang Z et al.: Co-evolution of a
broadly neutralizing HIV-1 antibody and founder virus. Nature
2013, 496:469-476.
58. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC,
Klasse PJ, Burton DR, Sanders RW, Moore JP et al.: Crystal
structure of a soluble cleaved HIV-1 envelope trimer. Science
2013, 342:1477-1483.
59. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ,
Burton DR, Sanders RW, Moore JP, Carragher B et al.: Cryo-EM
structure of a fully glycosylated soluble cleaved HIV-1
envelope trimer. Science 2013, 342:1484-1490.
60. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J,
Huang J, Acharya P, Chuang G-Y, Ofek G et al.: Structure and




Haynes BF, Kelsoe G, Harrison SC, Kepler TB: B-cell-lineage
immunogen design in vaccine development with HIV-1 as a
case study. Nat Biotechnol 2012, 30:423-433.
Outlines the rationale and methodology for B cell lineage vaccine design.Current Opinion in Immunology 2016, 41:62–67
